Gary Gordon

12.0k total citations
105 papers, 4.4k citations indexed

About

Gary Gordon is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gary Gordon has authored 105 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 23 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gary Gordon's work include Cancer Treatment and Pharmacology (14 papers), Hormonal and reproductive studies (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Gary Gordon is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Hormonal and reproductive studies (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Gary Gordon collaborates with scholars based in United States, United Kingdom and Canada. Gary Gordon's co-authors include D. Fournier, Yuesheng Zhang, Stephen P. Spielberg, Harlan F. Weisman, David A. Blake, Lisa M. Shantz, Paul Talalay, David E. Bush, Gary J. Kelloff and Ronald A. Lubet and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Gary Gordon

101 papers receiving 4.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Gordon United States 35 1.4k 1.0k 718 705 623 105 4.4k
Jeannette Bigler United States 42 1.8k 1.2× 1.2k 1.2× 849 1.2× 297 0.4× 680 1.1× 80 5.5k
Lei Shen China 34 1.1k 0.8× 663 0.7× 550 0.8× 603 0.9× 446 0.7× 119 6.4k
Desmond J. Fitzgerald Ireland 53 1.9k 1.3× 667 0.7× 519 0.7× 425 0.6× 1.9k 3.0× 164 10.1k
Julie F. Foley United States 47 2.7k 1.8× 912 0.9× 643 0.9× 944 1.3× 302 0.5× 128 6.3k
Takayoshi Toyota Japan 40 1.3k 0.9× 683 0.7× 758 1.1× 1.1k 1.6× 244 0.4× 249 6.4k
Noriaki Kume Japan 47 2.1k 1.5× 749 0.7× 195 0.3× 493 0.7× 963 1.5× 128 9.4k
Teake Kooistra Netherlands 40 2.0k 1.4× 472 0.5× 312 0.4× 599 0.8× 329 0.5× 97 6.4k
Anna S. Gukovskaya United States 54 2.4k 1.7× 2.7k 2.7× 580 0.8× 401 0.6× 558 0.9× 135 8.5k
Dror Harats Israel 45 2.1k 1.5× 330 0.3× 459 0.6× 572 0.8× 267 0.4× 209 7.1k
Xue Qin China 37 2.3k 1.6× 871 0.9× 375 0.5× 500 0.7× 231 0.4× 348 6.3k

Countries citing papers authored by Gary Gordon

Since Specialization
Citations

This map shows the geographic impact of Gary Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Gordon more than expected).

Fields of papers citing papers by Gary Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Gordon. The network helps show where Gary Gordon may publish in the future.

Co-authorship network of co-authors of Gary Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Gordon. A scholar is included among the top collaborators of Gary Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Gordon. Gary Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Groot, John Frederick De, Timothy F. Cloughesy, Donald A. Berry, et al.. (2024). Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2005–2005.
2.
3.
4.
Kasper, Bernd, Mrinal M. Gounder, Rashmi Chugh, et al.. (2023). 1929P phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors. Annals of Oncology. 34. S1037–S1037. 2 indexed citations
5.
Gounder, Mrinal M., et al.. (2023). Abstract CT070: Double-blind placebo-controlled trial of AL102 for treatment of progressing desmoid tumors: the RINGSIDE phase 3 study design. Cancer Research. 83(8_Supplement). CT070–CT070. 1 indexed citations
6.
7.
8.
Gordon, Gary, et al.. (2016). The Joy of SET. Princeton University Press eBooks.
9.
Meyskens, Frank L., Gregory A. Curt, Dean E. Brenner, et al.. (2011). Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic. Cancer Prevention Research. 4(3). 311–323. 36 indexed citations
10.
Lalla, Rajesh V., Gary Gordon, Mark Schubert, et al.. (2011). A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Supportive Care in Cancer. 20(8). 1797–1804. 20 indexed citations
11.
Kummar, Shivaani, Larry Rubinstein, Robert J. Kinders, et al.. (2009). Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP. Cancer Research. 69. 5456–5456. 6 indexed citations
12.
Mauer, Ann M., Ezra E.W. Cohen, C. Patrick, et al.. (2008). A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(6). 631–636. 78 indexed citations
13.
Ratain, Mark J., Rachel Humphrey, Gary Gordon, et al.. (2007). Recommended changes to oncology clinical trial design: Revolution or evolution?. European Journal of Cancer. 44(1). 8–11. 31 indexed citations
14.
Heath, E., Marcia Irene Canto, Steven Piantadosi, et al.. (2003). Chemoprevention for Barrett’s Esophagus Trial. Design and outcome measures. Diseases of the Esophagus. 16(3). 177–186. 29 indexed citations
15.
Gordon, Gary, et al.. (1991). Induction of NAD(P)H:quinone reductase in human peripheral blood lymphocytes. Carcinogenesis. 12(12). 2393–2396. 25 indexed citations
16.
Beveridge, Roy, et al.. (1991). High-Dose Chemotherapy With Reinfusion of Purged Autologous Bone Marrow Following Dose-Intense Induction as Initial Therapy for Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 83(13). 920–926. 131 indexed citations
17.
Gordon, Gary & Lorenzo Traldi. (1990). Generalized activities and the tutte polynomial. Discrete Mathematics. 85(2). 167–176. 29 indexed citations
18.
Gordon, Gary, et al.. (1989). A Greedoid Polynomial Which Distinguishes Rooted Arborescences. Proceedings of the American Mathematical Society. 107(2). 287–287. 10 indexed citations
19.
Holtzclaw, W. David & Gary Gordon. (1989). Measurement of serum levels of dehydroepiandrosterone sulfate: A comparison of radioimmunoassay and enzymatic analysis. Steroids. 54(4). 355–371. 14 indexed citations
20.
Gordon, Gary, David E. Bush, & Harlan F. Weisman. (1988). Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury.. Journal of Clinical Investigation. 82(2). 712–720. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeannette Bigler Breakdown of academic impact, for papers by Lei Shen Breakdown of academic impact, for papers by Desmond J. Fitzgerald Breakdown of academic impact, for papers by Julie F. Foley Breakdown of academic impact, for papers by Takayoshi Toyota Breakdown of academic impact, for papers by Noriaki Kume Breakdown of academic impact, for papers by Teake Kooistra Breakdown of academic impact, for papers by Anna S. Gukovskaya Breakdown of academic impact, for papers by Dror Harats Breakdown of academic impact, for papers by Xue Qin
Rankless by CCL
2026